Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Hazardous substances directive

You may also be interested in...



Europe In Brief

Guidance on revisions to Medical Device Directives: On June 5, the European Commission issued 1guidance on revisions made to the Medical Device Directives in 2007 that will take effect on March 21, 2010 via Directive 2007/47/EC (2"The Gray Sheet" June 1, 2009). The guidelines recommend that manufacturers of new types of devices, devices that have been reclassified under the revised classification rules and devices undergoing changes subject to prior assessment by a notified body complete a conformity assessment by a notified body before that date. Products already on the market prior to the 2010 deadline to which the revisions do not apply will only be subject to general market surveillance provisions. Manufacturers of all classes of devices on the market before the 2010 deadline must issue a Declaration of Conformity for that device stating compliance with Directives 90/385/EEC or 93/42/EEC, as amended by Directive 2007/47/EC. If the device's conformity evaluation requires a notified body, that notified body must check compliance with the new legislation

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel